Description

Glimepirid-TEVA Tablets 3 mg. №30

Composition:

Each tablet contains 3 mg of Glimepiride.

Mechanism of Action:

Glimepiride, a sulfonylurea, increases insulin release from the pancreas, leading to decreased blood sugar levels.

Pharmacological Properties:

Glimepirid-TEVA tablets belong to the sulfonylurea class of antidiabetic agents, promoting insulin secretion and improving glucose utilization in the body.

Indications for Use:

Glimepirid-TEVA tablets are specifically indicated for the treatment of type 2 diabetes mellitus.

Contraindications:

Avoid the use of Glimepirid-TEVA tablets in patients with type 1 diabetes or diabetic ketoacidosis due to potential adverse effects.

Side Effects:

Common side effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Monitor for any unusual symptoms and seek medical advice if necessary.

Usage Instructions:

Administer Glimepirid-TEVA tablets as prescribed by a healthcare professional, typically once daily with a meal to optimize efficacy.

Benefits Compared to Analogues:

Glimepiride has demonstrated effectiveness in improving glycemic control and reducing HbA1c levels, showing favorable outcomes compared to other antidiabetic agents.

Suitable Patient Groups:

Glimepirid-TEVA tablets are suitable for adult patients with type 2 diabetes, including the elderly population, but not recommended for children without medical supervision.

Storage and Shelf Life:

Store Glimepirid-TEVA tablets in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use expired medication.

Packaging Description:

Glimepirid-TEVA tablets are packaged in blister packs containing 30 tablets each, ensuring convenient and accurate dosing.

Clinical Evidence and Effectiveness:

Research in the Journal of Diabetes Investigation has highlighted the efficacy of Glimepiride in enhancing glycemic control and overall glucose management in patients with type 2 diabetes. Clinical trials have consistently shown positive outcomes with the use of Glimepirid-TEVA tablets.